TerminatedNot Applicable

CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation

Stopped: lack of resources (personnel and budget)

Belgium24 participantsStarted 2019-10-28

Plain-language summary

Lung transplantation is the ultimate treatment for end stage lung diseases. Survival after lung transplantation is limited mainly due to the development of chronic allograft dysfunction (CLAD). Both acute cellular rejection and primary grade dysfunction (PGD) have been associated with the development of CLAD. In this study we will investigate multiple prognostic factors that influence long term survival after lung transplantation with a specific interest in PGD, acute rejection and the development of CLAD.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * all lung transplant recipients \> 18 years signed ICF (informed consent form) Exclusion Criteria: * none

What they're measuring

identify prognostic biomarkers in blood, bronchoalveolar lavage and exhaled breath that will determine long term survival after human lung transplantation.

Timeframe: up to 520 weeks

Trial details

NCT IDNCT04558333

SponsorUniversity Hospital, Antwerp

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-02-28

View on ClinicalTrials.gov More Lung Transplant Failure and Rejection trials